Literature DB >> 21246024

Deficits in the management of patients with adrenocortical carcinoma in Germany.

Sarah Johanssen1, Stefanie Hahner, Wolfgang Saeger, Marcus Quinkler, Felix Beuschlein, Henning Dralle, Michaela Haaf, Matthias Kroiss, Christian Jurowich, Peter Langer, Wolfgang Oelkers, Martin Spahn, Holger S Willenberg, Uwe Mäder, Bruno Allolio, Martin Fassnacht.   

Abstract

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor with a poor prognosis. Often, the physicians who first treat patients with ACC have no prior experience with the disease. The aim of our study was to evaluate the quality of medical care for patients with ACC in Germany.
METHODS: Data from the German ACC registry were analyzed with regard to the patients' preoperative diagnostic evaluation, histopathological reporting, and clinical follow-up. The findings were compared with the recommendations of the European Network for the Study of Adrenal Tumors (ENSAT).
RESULTS: Data were analyzed from 387 patients who had been given an initial diagnosis of ACC in the years 1998 to 2009. 21% of them underwent no hormonal evaluation before surgery, and 59% underwent an inadequate hormonal evaluation. This exposed the patients to unnecessary perioperative risks and impaired their follow-up. 48% did not undergo CT scanning of the chest, even though the lungs are the most frequent site of metastases of ACC. For 13% of the patients, the diagnosis of ACC was later revised by a reference pathologist. For 11% of the patients, the histopathology report contained no information about resection status, even though this is an important determinant of further treatment and prognosis. Optimal management requires re-staging at three-month intervals, yet some patients underwent re-staging only after a longer delay, or not at all.
CONCLUSION: We have identified significant deficits in the care of patients with ACC in Germany. We suspect that the situation is similar for other rare diseases. The prerequisite to better care is close and early cooperation of the treating physicians with specialized centers.

Entities:  

Mesh:

Year:  2010        PMID: 21246024      PMCID: PMC3021904          DOI: 10.3238/arztebl.2010.0885

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  34 in total

Review 1.  Predisposing factors for adrenal insufficiency.

Authors:  Stefan R Bornstein
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

2.  Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.

Authors:  Martin Fassnacht; Stefanie Hahner; Buelent Polat; Ann-Cathrin Koschker; Werner Kenn; Michael Flentje; Bruno Allolio
Journal:  J Clin Endocrinol Metab       Date:  2006-08-08       Impact factor: 5.958

Review 3.  Management of patients with adrenal cancer: recommendations of an international consensus conference.

Authors:  D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

4.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

5.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

Authors:  Gwenaelle Abiven; Joel Coste; Lionel Groussin; Philippe Anract; Frédérique Tissier; Paul Legmann; Bertrand Dousset; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2006-05-02       Impact factor: 5.958

6.  Management of the clinically inapparent adrenal mass ("incidentaloma").

Authors:  Melvin M Grumbach; Beverly M K Biller; Glenn D Braunstein; Karen K Campbell; J Aidan Carney; Paul A Godley; Emily L Harris; Joseph K T Lee; Yolanda C Oertel; Mitchell C Posner; Janet A Schlechte; H Samuel Wieand
Journal:  Ann Intern Med       Date:  2003-03-04       Impact factor: 25.391

Review 7.  Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review.

Authors:  Sherita H Golden; Karen A Robinson; Ian Saldanha; Blair Anton; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2009-06       Impact factor: 5.958

Review 8.  NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma").

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Feb 4-6

Review 9.  Adrenocortical cancer: pathophysiology and clinical management.

Authors:  Rossella Libè; Amato Fratticci; Jérôme Bertherat
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

10.  An eleven-year experience with adrenocortical carcinoma.

Authors:  R F Pommier; M F Brennan
Journal:  Surgery       Date:  1992-12       Impact factor: 3.982

View more
  15 in total

Review 1.  [Surgical strategies for non-metastatic adrenocortical carcinoma].

Authors:  N Rayes; M Quinkler; T Denecke
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

2.  Adrenocortical carcinoma: effect of hospital volume on patient outcome.

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Marco Boniardi; Giorgio De Toma; Luigi Antonio Marzano; Paolo Miccoli; Francesco Minni; Mario Morino; Maria Rosa Pelizzo; Andrea Pietrabissa; Andrea Renda; Andrea Valeri; Carmela De Crea; Rocco Bellantone
Journal:  Langenbecks Arch Surg       Date:  2011-11-09       Impact factor: 3.445

3.  Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.

Authors:  Matthias Kroiss; Silviu Sbiera; Sabine Kendl; Max Kurlbaum; Martin Fassnacht
Journal:  Horm Cancer       Date:  2016-09-08       Impact factor: 3.869

4.  Deficits in the management of patients with adrenocortical carcinoma in Germany. Statements cannot be substantiated.

Authors:  Manfred Dietel; Peter Schirmacher
Journal:  Dtsch Arztebl Int       Date:  2011-05-13       Impact factor: 5.594

5.  Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience.

Authors:  Marilyne Daher; Jeena Varghese; Stephen K Gruschkus; Camilo Jimenez; Steven G Waguespack; Sara Bedrose; Lina Altameemi; Hadil Bazerbashi; Aung Naing; Vivek Subaiah; Matthew T Campbell; Amishi Y Shah; Miao Zhang; Rahul A Sheth; Jose A Karam; Christopher G Wood; Nancy D Perrier; Paul H Graham; Jeffery E Lee; Mouhammed Amir Habra
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

6.  Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome.

Authors:  Andrew R Williams; Gary D Hammer; Tobias Else
Journal:  Eur J Endocrinol       Date:  2014-06       Impact factor: 6.664

7.  Adrenocortical carcinoma: modern management and evolving treatment strategies.

Authors:  Lucas A McDuffie; Rachel D Aufforth
Journal:  Int J Endocr Oncol       Date:  2016-04-08

Review 8.  Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.

Authors:  Kerollos N Wanis; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2015-03-24       Impact factor: 2.754

9.  Adrenocortical carcinoma: presentation and outcome of a contemporary patient series.

Authors:  Iiro Kostiainen; Liisa Hakaste; Pekka Kejo; Helka Parviainen; Tiina Laine; Eliisa Löyttyniemi; Mirkka Pennanen; Johanna Arola; Caj Haglund; Ilkka Heiskanen; Camilla Schalin-Jäntti
Journal:  Endocrine       Date:  2019-04-12       Impact factor: 3.925

10.  European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy.

Authors:  Bertil Ekman; David Fitts; Claudio Marelli; Robert D Murray; Marcus Quinkler; Pierre M J Zelissen
Journal:  BMC Endocr Disord       Date:  2014-05-09       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.